Health Canada Approves KYZATREX Oral Testosterone Therapy, Expanding Treatment Options for Canadian Men
核心洞察
Health Canada has approved KYZATREX (testosterone undecanoate) capsules, marking the first oral testosterone replacement therapy available in softgel form for Canadian men with testosterone deficiency (搜索).
The approval addresses a significant medical need, with approximately 25% of Canadian men aged 40-62 years (roughly 3 million men) estimated to have biochemical testosterone deficiency (搜索).
Clinical trial data showed 88% of patients achieved normal testosterone levels, with the oral formulation offering a convenient alternative to injectable or transdermal treatments.
Marius Pharmaceuticals announced that Health Canada has approved KYZATREX (testosterone undecanoate) CIII capsules for treating adult men with low or no testosterone levels due to certain medical conditions. This regulatory milestone makes KYZATREX the only oral testosterone replacement therapy available in softgel capsule form in Canada, expanding treatment options beyond the U.S. market where it received FDA approval in August 2022.
Addressing Significant Unmet Medical Need
The approval comes at a critical time for men's health in Canada, where testosterone deficiency (搜索) represents a substantial clinical burden. According to company data, the crude prevalence of biochemical testosterone deficiency is estimated at approximately 25% among Canadian men aged 40-62 years, affecting roughly 3 million men. Testosterone deficiency, also known as hypogonadism (搜索), manifests through symptoms including low libido, fatigue, muscle weakness, mood disturbances, and metabolic dysfunction.
"Today's approval of KYZATREX by Health Canada is a major milestone for Marius Pharma and for men's health in Canada," said Amit Shah, Chief Operating Officer of Marius Pharmaceuticals. "We recognize the burden that testosterone deficiency (搜索) places on men's physical, cognitive, and metabolic health, and we are committed to expanding access to effective, convenient treatment options."
Clinical Evidence Supporting Approval
The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study involving 155 hypogonadal males between 18 and 65 years of age. All participants had documented hypogonadism (搜索), defined by below-normal serum testosterone levels (≤281 ng/dL) and at least one sign or symptom of testosterone deficiency (搜索).
In the efficacy-evaluable population of 139 patients, 88% achieved the primary endpoint of mean plasma total testosterone concentration over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic visit at Day 90. Patients started with 200 mg twice daily with meals, with doses titrated over two 28-day cycles between 100 mg and 800 mg daily.
Patient-Reported Outcomes and Safety Profile
Beyond achieving target testosterone levels, patients receiving KYZATREX reported improvements across multiple symptom domains based on exploratory endpoints. These included enhanced quality of life, reduced energy and fatigue issues, improved erectile function, better sexual intercourse experiences, and mood improvements.
The treatment demonstrated a favorable safety profile with no drug-related serious adverse events reported. The most common side effect was increased blood pressure, occurring in 2.6% of patients. The formulation's unique absorption pathway through the lymphatic system means it is not toxic to the liver, distinguishing it from other oral testosterone preparations.
Market Launch Strategy
Marius Pharmaceuticals plans to launch KYZATREX in the Canadian market in the first half of 2026, making it available through both telehealth and traditional provider options. The company emphasized its commitment to working collaboratively with Canadian healthcare providers to ensure appropriate patient access, education, and monitoring.
The oral softgel formulation presents a convenient alternative to existing injectable or transdermal testosterone replacement therapies, potentially improving treatment adherence and patient satisfaction. This approval follows Marius's submission to Health Canada in July 2024 and represents the company's first international expansion beyond the U.S. market.